Full-Time

Director Technology Development Research

Updated on 9/4/2026

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$190.7k - $291.5k/yr

+ Annual bonus + Long-term incentive program

La Jolla, San Diego, CA, USA

In Person

Requires up to 15% domestic and international travel.

PhD

Category
Biology & Biotech (1)
Required Skills
GMP

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • A Ph.D. in Biological Sciences, Immunology, Molecular Biology, Biochemistry, or a closely related discipline is required.
  • At least 10 years of experience in the biopharmaceutical industry, including significant cell therapy research experience and strong expertise in stem cell biology and iPSC-derived immune cell platforms.
  • Hands-on experience with human iPSC culture, immune cell differentiation, phenotypic and functional characterization, and cell engineering approaches, including genome editing and viral or non-viral delivery methods.
  • Experience translating early-stage research and process development into CMC-relevant deliverables, including process characterization, analytical strategy, documentation, and technology transfer support.
  • Experience advancing cell and gene therapy programs toward IND submission and integrating scientific, translational, CMC, regulatory, and external partner inputs into a coherent development strategy.
  • Deep understanding of relevant regulatory guidelines and quality frameworks, including GMP, ISO, and ICH.
  • Experience selecting, managing, and providing scientific oversight of CROs and CDMOs.
  • Experience serving as the accountable scientific lead for assigned projects and providing strategic guidance and data-driven experimental decision-making.
  • Strong scientific expertise in stem cell biology, immunology, cancer biology, and cell therapy platform development.
  • Deep technical understanding of iPSC culture, cell differentiation, cellular engineering, genome editing, viral and non-viral delivery, and molecular biology.
  • Experience with immune cell characterization methods, including flow cytometry, immunostaining, functional assays, and related analytical approaches.
  • Ability to interpret complex scientific, translational, and CMC-relevant data and translate findings into clear recommendations.
  • Proficiency with Microsoft Office Suite.
  • Up to 15% domestic and international travel is required.
Responsibilities
  • Lead the Technology Development Research group responsible for allogeneic immune cell therapy research, cell and gene therapy technology development, platform capability expansion, and genome editing capabilities.
  • Define scientific strategy for technology projects and platform initiatives, including goals, milestones, decision criteria, risks, and resource needs aligned with portfolio priorities.
  • Oversee execution of research plans led by project leaders and scientists, ensuring timely delivery of high-quality data and recommendations for project and portfolio decisions.
  • Provide senior-level technical leadership in iPSC biology, immune cell differentiation, cellular engineering, genome editing, viral and non-viral delivery, and molecular biology.
  • Translate early-stage research outputs into development-ready data packages, including CMC-relevant elements such as process characterization, analytical strategy, potency and functional assays, comparability, and documentation.
  • Propose, prioritize, and lead technology initiatives and enhancements to strengthen the cell therapy portfolio.
  • Manage, mentor, and develop project leaders, scientists, and research staff.
  • Oversee resource planning, personnel prioritization, external partner engagement, and budget input for assigned projects and technology initiatives.
  • Represent Technology Research in governance discussions, project reviews, scientific forums, and selected external engagements.
  • Prepare, review, and endorse project documentation.
  • Ensure research activities comply with internal policies, external standards, and regulatory expectations.
Desired Qualifications
  • Direct experience engaging with the FDA or other health authorities for cell therapy products.
  • Experience leading development, qualification, or validation of potency assays and other quality-control release assays.
  • CAR immune cell engineering experience.
  • Strong written and verbal communication skills for presenting complex scientific and strategic topics to senior stakeholders.
  • Ability to organize, prioritize, meet deadlines, make decisions, and adapt as priorities evolve.
  • Ability to build consensus and collaborate across functions, geographies, and working styles within a multinational organization.
  • Strong interpersonal skills and ability to mentor, influence, and develop scientific talent.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for PreCheck on June 30, 2026, accelerating biologics launch readiness.
  • Crysvita expanded adult XLH dosing in May 2026, extending treatment uptake and persistence.
  • 2025 revenue reached ¥496.8 billion, and 2026 guidance rises to ¥520.0 billion.

What critics are saying

  • Crysvita sales still dominate; any reimbursement squeeze or safety issue hits 2026 results fast.
  • Sanford slips past 2027, and the FDA PreCheck advantage evaporates into delay and cost.
  • March 2026 leadership turnover, including CFO Motohiko Kawaguchi, disrupts execution and accountability.

What makes Kyowa Kirin unique

  • Crysvita remains the only approved XLH therapy, protecting a rare-disease franchise in 2026.
  • Sanford, North Carolina gives Kyowa Kirin a first U.S. biologics manufacturing base by 2027.
  • Benchling deployment in Tokyo and Fuji formalizes AI-enabled R&D workflows across discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.